Diverse roles of arrest defective 1 in cancer development

Arch Pharm Res. 2019 Dec;42(12):1040-1051. doi: 10.1007/s12272-019-01195-0. Epub 2019 Dec 7.

Abstract

Arrest defective 1 is an acetyltransferase that acetylates N-terminal amino acid or internal lysine residues of its target proteins. By acetylating its target proteins, ARD1 plays roles in many cellular activities, including proliferation, differentiation, autophagy, and apoptosis. In recent years, a number of investigations have emerged reporting the dysregulated expression of ARD1 in different types of cancer, including lung, liver, pancreas, breast, prostate, and colon cancer. Furthermore, the expression level of ARD1 in cancer tissues has been correlated with the progression and metastasis of the cancer and the survival of cancer patients. Consequently, mechanistic studies have revealed that ARD1-mediated protein acetylation plays an important role in modulating several cellular events that are important for cancer development, such as cell cycle progression, cell death, and migration. On the basis of this evidence, targeting of ARD1 has been proposed as a promising avenue for the development of novel cancer therapeutics. This review summarizes the biological functions of ARD1 in different types of cancer and provides a deep insight into the biochemical activities of ARD1 during tumor progression.

Keywords: ARD1; Acetylation; Acetyltransferase; Tumorigenesis.

Publication types

  • Review

MeSH terms

  • Humans
  • N-Terminal Acetyltransferase A / genetics
  • N-Terminal Acetyltransferase A / metabolism*
  • N-Terminal Acetyltransferase E / genetics
  • N-Terminal Acetyltransferase E / metabolism*
  • Neoplasms / metabolism*
  • Neoplasms / pathology

Substances

  • N-Terminal Acetyltransferase A
  • NAA10 protein, human
  • N-Terminal Acetyltransferase E